Literature DB >> 7583269

Post-injury administration of BIBN 99, a selective muscarinic M2 receptor antagonist, improves cognitive performance following traumatic brain injury in rats.

B R Pike1, R J Hamm.   

Abstract

Mild to moderate traumatic brain injury (TBI) is associated with enduring impairments of cognitive function in both humans and animals. However, few experiments have investigated the role of post-injury pharmacologic strategies for attenuating the observed cognitive impairment after TBI. This investigation examined the effects of selective blockade of the presynaptic muscarinic M2 autoreceptor with BIBN 99 on cognitive recovery following rodent TBI. Experiment 1 investigated the effects of delayed post-injury administration of BIBN 99 on cognitive performance following moderate central fluid percussion TBI (2.1 +/- 0.05 atm). On days 11-15 after injury-cognitive performance was assessed with a Morris water maze (MWM) task. One hour before MWM testing injured rats were injected (s.c.) with either vehicle (n = 9), 0.5 (n = 8), or 1.0 (n = 8) mg/kg of BIBN 99. Results indicated that injured rats receiving the delayed post-injury treatment with BIBN 99 performed no better than injured-vehicle treated rats. In experiment 2, injured rats were injected (s.c.) once daily with either vehicle (n = 9), 0.5 (n = 9), or 1.0 (n = 9) mg/kg of BIBN 99 throughout the duration of the experiment beginning 24 h after TBI. Sham-injured animals injected (s.c.) with vehicle (n = 9) or 1.0 (n = 8) mg/kg of BIBN 99 were included for comparison. On days 11-15 after injury, cognitive performance was assessed with the MWM procedure. Results of the second experiment indicated that both doses of BIBN 99 were effective in attenuating cognitive deficits in the MWM as compared to the injured-vehicle treated animals (P < 0.05 for both comparisons).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7583269     DOI: 10.1016/0006-8993(95)00448-y

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  8 in total

Review 1.  A review of neuroprotection pharmacology and therapies in patients with acute traumatic brain injury.

Authors:  Kevin W McConeghy; Jimmi Hatton; Lindsey Hughes; Aaron M Cook
Journal:  CNS Drugs       Date:  2012-07-01       Impact factor: 5.749

2.  Post-Injury Administration of Galantamine Reduces Traumatic Brain Injury Pathology and Improves Outcome.

Authors:  Jing Zhao; Michael J Hylin; Nobuhide Kobori; Kimberly N Hood; Anthony N Moore; Pramod K Dash
Journal:  J Neurotrauma       Date:  2017-12-18       Impact factor: 5.269

Review 3.  Neurotransmitter changes after traumatic brain injury: an update for new treatment strategies.

Authors:  Jennifer L McGuire; Laura B Ngwenya; Robert E McCullumsmith
Journal:  Mol Psychiatry       Date:  2018-09-13       Impact factor: 15.992

Review 4.  Alterations in Cholinergic Pathways and Therapeutic Strategies Targeting Cholinergic System after Traumatic Brain Injury.

Authors:  Samuel S Shin; C Edward Dixon
Journal:  J Neurotrauma       Date:  2015-06-29       Impact factor: 5.269

Review 5.  Pharmacological treatment of traumatic brain injury: a review of agents in development.

Authors:  J Hatton
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

6.  Acetylcholine mediates the estrogen-induced increase in NMDA receptor binding in CA1 of the hippocampus and the associated improvement in working memory.

Authors:  J M Daniel; G P Dohanich
Journal:  J Neurosci       Date:  2001-09-01       Impact factor: 6.167

7.  Donepezil is ineffective in promoting motor and cognitive benefits after controlled cortical impact injury in male rats.

Authors:  Kaitlyn E Shaw; Corina O Bondi; Samuel H Light; Lire A Massimino; Rose L McAloon; Christina M Monaco; Anthony E Kline
Journal:  J Neurotrauma       Date:  2013-03-26       Impact factor: 5.269

8.  Spatial Distribution of Neuropathology and Neuroinflammation Elucidate the Biomechanics of Fluid Percussion Injury.

Authors:  Joshua A Beitchman; Jonathan Lifshitz; Neil G Harris; Theresa Currier Thomas; Audrey D Lafrenaye; Anders Hånell; C Edward Dixon; John T Povlishock; Rachel K Rowe
Journal:  Neurotrauma Rep       Date:  2021-02-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.